Trial Profile

Efficacy and safety of everolimus and exemestane in treatment of advanced breast cancer.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Exemestane
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms BRAWO

Most Recent Events

06 Jun 2017 Updated results of 3rd interim analysis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
02 Jun 2017 Results (data cut-off 18 Oct 2016; n=1345) of third interim analysis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
12 Dec 2015 3rd Interim results (n=1300) presented at the 38th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com